Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS).

Mitsumoto H, Chiuzan C, Gilmore M, Zhang Y, Ibagon C, McHale B, Hupf J, Oskarsson B.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):328-335. doi: 10.1080/21678421.2019.1603310. Epub 2019 Apr 22. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2019 Jun 11;:1.

PMID:
31007059
2.

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.

van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H; Airlie House ALS Clinical Trials Guidelines Group.

Neurology. 2019 Apr 2;92(14):e1610-e1623. doi: 10.1212/WNL.0000000000007242. Epub 2019 Mar 8.

3.

Sexuality and intimacy in ALS: systematic literature review and future perspectives.

Poletti B, Carelli L, Solca F, Pezzati R, Faini A, Ticozzi N, Mitsumoto H, Silani V.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):712-719. doi: 10.1136/jnnp-2018-319684. Epub 2018 Dec 11. Review.

PMID:
30538137
4.

Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients.

Woolley S, Goetz R, Factor-Litvak P, Murphy J, Hupf J, Lomen-Hoerth C, Andrews H, Heitzman D, Bedlack R, Katz J, Barohn R, Sorenson E, Oskarsson B, Filho AF, Kasarskis E, Mozaffar T, Nations S, Swenson A, Koczon-Jaremko A, Christodoulou G, Mitsumoto H.

Behav Neurol. 2018 Oct 31;2018:5969137. doi: 10.1155/2018/5969137. eCollection 2018.

5.

[A prognostic biomarker in amyotrophic lateral sclerosis].

Mitsumoto H, Saito T.

Rinsho Shinkeigaku. 2018 Dec 21;58(12):729-736. doi: 10.5692/clinicalneurol.cn-001220. Epub 2018 Nov 29. Review. Japanese.

PMID:
30487362
6.

Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium.

Muscle Nerve. 2019 Feb;59(2):201-207. doi: 10.1002/mus.26335. Epub 2018 Nov 26.

PMID:
30192007
7.

Understanding the use of NIV in ALS: results of an international ALS specialist survey.

Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):331-341. doi: 10.1080/21678421.2018.1457058. Epub 2018 Apr 16.

PMID:
29661084
8.

What if you knew the prognosis of your patients with ALS?

Mitsumoto H.

Lancet Neurol. 2018 May;17(5):386-388. doi: 10.1016/S1474-4422(18)30111-X. Epub 2018 Mar 26. No abstract available.

PMID:
29598921
9.

Respiratory measures in amyotrophic lateral sclerosis.

Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):321-330. doi: 10.1080/21678421.2018.1452945. Epub 2018 Mar 23. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):478.

PMID:
29566571
10.

Hydration measured by doubly labeled water in ALS and its effects on survival.

Scagnelli CN, Howard DB, Bromberg MB, Kasarskis EJ, Matthews DE, Mitsumoto HM, Simmons Z, Tandan R; ALS Nutrition-NIPPV Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):220-231. doi: 10.1080/21678421.2017.1413117. Epub 2017 Dec 15.

PMID:
29243507
11.

Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients.

Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, Cajamarca SA, Hupf JC, Ravits JM, Miller TM, Maragakis NJ, Hales CM, Glass JD, Gross S, Mitsumoto H, Manfredi G.

Mol Neurodegener. 2017 Oct 24;12(1):76. doi: 10.1186/s13024-017-0217-5.

12.

Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy.

Mitsumoto H.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1004-1005. doi: 10.1136/jnnp-2017-316209. Epub 2017 Aug 9. No abstract available.

PMID:
28794153
13.

Improving symptom management for people with amyotrophic lateral sclerosis.

Nicholson K, Murphy A, McDonnell E, Shapiro J, Simpson E, Glass J, Mitsumoto H, Forshew D, Miller R, Atassi N.

Muscle Nerve. 2018 Jan;57(1):20-24. doi: 10.1002/mus.25712. Epub 2017 Jul 1.

PMID:
28561886
14.

Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis.

Nieves JW, Gennings C, Factor-Litvak P, Hupf J, Singleton J, Sharf V, Oskarsson B, Fernandes Filho JA, Sorenson EJ, D'Amico E, Goetz R, Mitsumoto H; Amyotrophic Lateral Sclerosis Multicenter Cohort Study of Oxidative Stress (ALS COSMOS) Study Group.

JAMA Neurol. 2016 Dec 1;73(12):1425-1432. doi: 10.1001/jamaneurol.2016.3401.

15.

Cognitive impairment, behavioral impairment, depression, and wish to die in an ALS cohort.

Rabkin J, Goetz R, Murphy JM, Factor-Litvak P, Mitsumoto H; ALS COSMOS Study Group.

Neurology. 2016 Sep 27;87(13):1320-8. doi: 10.1212/WNL.0000000000003035. Epub 2016 Aug 5.

16.

ALS and physician-assisted suicide.

Katz J, Mitsumoto H.

Neurology. 2016 Sep 13;87(11):1072-3. doi: 10.1212/WNL.0000000000002969. Epub 2016 Jul 8. No abstract available.

PMID:
27402892
17.

Telephone based cognitive-behavioral screening for frontotemporal changes in patients with amyotrophic lateral sclerosis (ALS).

Christodoulou G, Gennings C, Hupf J, Factor-Litvak P, Murphy J, Goetz RR, Mitsumoto H.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):482-488. Epub 2016 Apr 28.

18.

Phenotypic and molecular analyses of primary lateral sclerosis.

Mitsumoto H, Nagy PL, Gennings C, Murphy J, Andrews H, Goetz R, Floeter MK, Hupf J, Singleton J, Barohn RJ, Nations S, Shoesmith C, Kasarskis E, Factor-Litvak P.

Neurol Genet. 2015 Apr 14;1(1):e3. doi: 10.1212/01.NXG.0000464294.88607.dd. eCollection 2015 Jun.

19.

Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population.

Fournier CN, Murphy A, Loci L, Mitsumoto H, Lomen-Hoerth C, Kisanuki Y, Simmons Z, Maragakis NJ, McVey AL, Al-Lahham T, Heiman-Patterson TD, Andrews J, McDonnell E, Cudkowicz M, Atassi N.

J Clin Neuromuscul Dis. 2016 Mar;17(3):99-105. doi: 10.1097/CND.0000000000000102.

20.

Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.

Sansone VA, Burge J, McDermott MP, Smith PC, Herr B, Tawil R, Pandya S, Kissel J, Ciafaloni E, Shieh P, Ralph JW, Amato A, Cannon SC, Trivedi J, Barohn R, Crum B, Mitsumoto H, Pestronk A, Meola G, Conwit R, Hanna MG, Griggs RC; Muscle Study Group.

Neurology. 2016 Apr 12;86(15):1408-1416. doi: 10.1212/WNL.0000000000002416. Epub 2016 Feb 10.

21.

Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.

Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS.

Neurology. 2016 Mar 1;86(9):813-20. doi: 10.1212/WNL.0000000000002305. Epub 2016 Jan 22.

22.

Non-invasive measurement of abnormal ventilatory mechanics in amyotrophic lateral sclerosis.

Layton AM, Moran SL, Roychoudhury A, Hupf J, Thomashow BM, Mitsumoto H.

Muscle Nerve. 2016 Aug;54(2):270-6. doi: 10.1002/mus.25043. Epub 2016 Jun 22.

PMID:
26800304
23.

The Dilemma of the Clinical Trialist in Amyotrophic Lateral Sclerosis: The Hurdles to Finding a Cure.

Katz JS, Barohn RJ, Dimachkie MM, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):937-47. doi: 10.1016/j.ncl.2015.07.014. Review.

PMID:
26515630
24.

Potential Environmental Factors in Amyotrophic Lateral Sclerosis.

Oskarsson B, Horton DK, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):877-88. doi: 10.1016/j.ncl.2015.07.009. Review.

25.

Primary Lateral Sclerosis.

Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):749-60. doi: 10.1016/j.ncl.2015.07.007. Epub 2015 Sep 8. Review.

26.

Opinions of Japanese and American ALS caregivers regarding tracheostomy with invasive ventilation (TIV).

Christodoulou G, Goetz R, Ogino M, Mitsumoto H, Rabkin J.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1-2):47-54. doi: 10.3109/21678421.2015.1069850. Epub 2015 Aug 24.

PMID:
26343785
27.

Relationship of creatine kinase to body composition, disease state, and longevity in ALS.

Gibson SB, Kasarskis EJ, Hu N, Pulst SM, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Kryscio RJ, Bromberg MB.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):473-7. doi: 10.3109/21678421.2015.1062516. Epub 2015 Aug 27.

28.

[The Current Status of End-of-Life Care in ALS: Progress and Personal Experience from the Past Ten Years in the USA].

Mitsumoto H.

Brain Nerve. 2015 Aug;67(8):993-1005. doi: 10.11477/mf.1416200245. Japanese.

PMID:
26241360
29.

Non-invasive ventilation and diaphragmatic pacing in ALS.

Mitsumoto H.

Lancet Neurol. 2015 Sep;14(9):868-869. doi: 10.1016/S1474-4422(15)00185-4. Epub 2015 Jul 30. No abstract available.

30.

Depression and wish to die in a multicenter cohort of ALS patients.

Rabkin JG, Goetz R, Factor-Litvak P, Hupf J, McElhiney M, Singleton J, Mitsumoto H; Als Cosmos Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2015 Jun;16(3-4):265-73. doi: 10.3109/21678421.2014.980428. Epub 2014 Dec 8.

31.

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

Mitsumoto H, Brooks BR, Silani V.

Lancet Neurol. 2014 Nov;13(11):1127-1138. doi: 10.1016/S1474-4422(14)70129-2. Review.

PMID:
25316019
32.

A new spectroelectrochemical cell for in situ measurement of Pt and Au K-edge X-ray absorption fine structure.

Kaito T, Mitsumoto H, Sugawara S, Shinohara K, Uehara H, Ariga H, Takakusagi S, Asakura K.

Rev Sci Instrum. 2014 Aug;85(8):084104. doi: 10.1063/1.4892531.

33.

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.

Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T Jr, Archibald D.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):406-13. doi: 10.3109/21678421.2014.943672. Epub 2014 Aug 15.

PMID:
25125035
34.

Seeking a measure of clinically meaningful change in ALS.

McElhiney M, Rabkin JG, Goetz R, Katz J, Miller RG, Forshew DA, David W, Cudkowicz M, Glass JD, Appel S, Simpson E, Mitsumoto H.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):398-405. doi: 10.3109/21678421.2014.942668. Epub 2014 Aug 15. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):627.

PMID:
25124889
35.

Bioenergetic markers in skin fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral sclerosis patients.

Kirk K, Gennings C, Hupf JC, Tadesse S, D'Aurelio M, Kawamata H, Valsecchi F, Mitsumoto H; ALS/PLS COSMOS Study Groups, Manfredi G.

Ann Neurol. 2014 Oct;76(4):620-4. doi: 10.1002/ana.24244. Epub 2014 Aug 21.

36.

Nuclear localization of SMN and FUS is not altered in fibroblasts from patients with sporadic ALS.

Kariya S, Sampson JB, Northrop LE, Luccarelli CM, Naini AB, Re DB, Hirano M, Mitsumoto H.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):581-7. doi: 10.3109/21678421.2014.907319. Epub 2014 May 9.

37.

Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique.

Weiduschat N, Mao X, Hupf J, Armstrong N, Kang G, Lange DJ, Mitsumoto H, Shungu DC.

Neurosci Lett. 2014 Jun 6;570:102-7. doi: 10.1016/j.neulet.2014.04.020. Epub 2014 Apr 24.

PMID:
24769125
38.

Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.

Goldman JS, Quinzii C, Dunning-Broadbent J, Waters C, Mitsumoto H, Brannagan TH 3rd, Cosentino S, Huey ED, Nagy P, Kuo SH.

JAMA Neurol. 2014 Jun;71(6):771-4. doi: 10.1001/jamaneurol.2013.5762.

39.

Japanese and American ALS patient preferences regarding TIV (tracheostomy with invasive ventilation): a cross-national survey.

Rabkin J, Ogino M, Goetz R, McElhiney M, Hupf J, Heitzman D, Heiman-Patterson T, Miller R, Katz J, Lomen-Hoerth C, Imai T, Atsuta N, Morita M, Tateishi T, Matsumura T, Mitsumoto H.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):185-91. doi: 10.3109/21678421.2014.896928. Epub 2014 Apr 10.

PMID:
24720451
40.

Amyotrophic lateral sclerosis: a long preclinical period?

Eisen A, Kiernan M, Mitsumoto H, Swash M.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1232-8. doi: 10.1136/jnnp-2013-307135. Epub 2014 Mar 19. Review.

PMID:
24648037
41.

Duplicated female receptacle organs for traumatic insemination in the tropical bed bug Cimex hemipterus: adaptive variation or malformation?

Kamimura Y, Mitsumoto H, Lee CY.

PLoS One. 2014 Feb 19;9(2):e89265. doi: 10.1371/journal.pone.0089265. eCollection 2014.

42.

Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz M; MDA Clinical Research Network.

Lancet. 2014 Jun 14;383(9934):2065-2072. doi: 10.1016/S0140-6736(14)60222-1. Epub 2014 Feb 28.

43.

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24.

44.

Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromberg MB, Kryscio RJ; ALS Nutrition/NIPPV Study Group.

Am J Clin Nutr. 2014 Apr;99(4):792-803. doi: 10.3945/ajcn.113.069997. Epub 2014 Feb 12.

45.

Necroptosis drives motor neuron death in models of both sporadic and familial ALS.

Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S, Ikiz B, Hoffmann L, Koolen M, Nagata T, Papadimitriou D, Nagy P, Mitsumoto H, Kariya S, Wichterle H, Henderson CE, Przedborski S.

Neuron. 2014 Mar 5;81(5):1001-1008. doi: 10.1016/j.neuron.2014.01.011. Epub 2014 Feb 6.

46.

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.

Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators.

Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Erratum in: Lancet Neurol. 2013 Nov;12(11):1042. Carbonell, J G [corrected to Gamez, J].

PMID:
24067398
47.

Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2.

Tazen S, Figueroa K, Kwan JY, Goldman J, Hunt A, Sampson J, Gutmann L, Pulst SM, Mitsumoto H, Kuo SH.

JAMA Neurol. 2013 Oct;70(10):1302-4.

48.

Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H.

Free Radic Biol Med. 2013 Dec;65:509-527. doi: 10.1016/j.freeradbiomed.2013.06.029. Epub 2013 Jun 21. Review.

49.

Infrastructure resources for clinical research in amyotrophic lateral sclerosis.

Sherman AV, Gubitz AK, Al-Chalabi A, Bedlack R, Berry J, Conwit R, Harris BT, Horton DK, Kaufmann P, Leitner ML, Miller R, Shefner J, Vonsattel JP, Mitsumoto H.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:53-61. doi: 10.3109/21678421.2013.779058. Review.

PMID:
23678880
50.

Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis.

Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, Floeter MK, Henderson C, Lomen-Hoerth C, Macklis JD, McCluskey L, Mitsumoto H, Przedborski S, Rothstein J, Trojanowski JQ, van den Berg LH, Ringel S.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:5-18. doi: 10.3109/21678421.2013.778548.

Supplemental Content

Loading ...
Support Center